

February 08, 2024

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: 512529

Symbol: SEQUENT

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has executed Deed of assignment on February 08, 2024, for sale of Plot No. 7 in the Ambernath Industrial Area, situated at Village Morivali, within the registration Sub District Kalyan, District Thane, admeasuring about 7,481 square metres.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed herewith as '**Annexure - I**'.

This is for your information and records.

Yours sincerely,

For **Sequent Scientific Limited**

Krunal Shah

Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

Details required under the Listing Regulations read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sale of Company's Plot No. 7 situated at Ambernath Industrial Area, Ambernath

Sr. No.	Particulars	Description
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Considering that the proposed sale is of an asset, the said details are not applicable.
2.	Date on which the agreement for sale has been entered into	February 08, 2024
3.	The expected date of completion of sale/disposal	February 08, 2024
4.	Consideration received from such sale/disposal	Rs. 7,82,34,000/- (including taxes)
5.	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Apex Buildcon, a Partnership Firm having its office on the 2 nd Floor, Shivom Palace, Nr. Shivneri Hospital, Block No. 208/416A, Ulhasnagar 421004, Maharashtra. The buyer is not a part of Promoter/Promoter Group/Group Companies as defined under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The buyer is not a Related Party in terms of Section 2(76) of the Companies Act, 2013, Regulation 2(zb) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable Accounting Standards.

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

7.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	N.A.
----	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------

SeQuent Scientific Limited